Previous 10 | Next 10 |
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA’s Clinical Studies Network Project NextGen is a $5 billion initiative by the U.S....
2024-06-07 16:40:29 ET More on GeoVax Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha For further details see: GeoVax files to sell 1.61M sha...
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin ® ATLANTA, GA - ( NewMediaWire ) - May 29, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunoth...
2024-05-23 08:48:04 ET Greenwave Technology Solutions ( GWAV ) +55% after eliminates all convertible debt . Ascent Solar Technologies ( ASTI ) +49% . Bicycle Therapeutics ( BCYC ) +14% after announces $555 million private placement equity financing ...
ATLANTA, GA - ( NewMediaWire ) - May 17, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certa...
2024-05-15 07:53:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Geovax Labs (NASDAQ: GOVX ) just reported results for the first quarter of 2024. Geovax Labs reported earnings per share of -$2.47. This was above the analyst estimate for...
2024-05-14 20:01:02 ET GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Conference Call May 14, 2024, 04:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer ...
2024-05-14 16:40:09 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate Significant milestone achieved towards implementation of a commercially validated manufacturing system Progress acr...
2024-05-13 17:35:36 ET Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. ( OXLC ) Capital Southwest Corporation ( CSWC ) Seadrill Limited ( SDRL ) Nu Holdings Ltd. ( NU ) Canoo ( GOEV ) Read the full articl...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...